NCT03316781View on ClinicalTrials.gov

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

262

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

July 15, 2018

Study Completion Date

April 22, 2019

Conditions
Plaque Psoriasis
Interventions
DRUG

HLX03

80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.

DRUG

adalimumab

80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT03316781 - Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter